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de Seigneux S, Nielsen J, Olesen ET, Dimke H, Kwon T-H,
Frøkiær J, Nielsen S. Long-term aldosterone treatment induces de-
creased apical but increased basolateral expression of AQP2 in CCD of
rat kidney. Am J Physiol Renal Physiol 293: F87–F99, 2007. First
published March 20, 2007; doi:10.1152/ajprenal.00431.2006.—The pur-
pose of the present studies was to determine the effects of high-dose
aldosterone and dDAVP treatment on renal aquaporin-2 (AQP2)
regulation and urinary concentration. Rats were treated for 6 days with
either vehicle (CON; n  8), dDAVP (0.5 ng/h, dDAVP, n  10),
aldosterone (Aldo, 150 g/day, n  10) or combined dDAVP and
aldosterone treatment (dDAVPAldo, n  10) and had free access to
water with a fixed food intake. Aldosterone treatment induced hypo-
kalemia, decreased urine osmolality, and increased the urine volume
and water intake in ALDO compared with CON and dDAVPAldo
compared with dDAVP. Immunohistochemistry and semiquantitative
laser confocal microscopy revealed a distinct increase in basolateral
domain AQP2 labeling in cortical collecting duct (CCD) principal
cells and a reduction in apical domain labeling in Aldo compared with
CON rats. Given the presence of hypokalemia in aldosterone-treated
rats, we studied dietary-induced hypokalemia in rats, which also
reduced apical AQP2 expression in the CCD but did not induce any
increase in basolateral AQP2 expression in the CCD as observed with
aldosterone treatment. The aldosterone-induced basolateral AQP2
expression in the CCD was thus independent of hypokalemia but was
dependent on the presence of sodium and aldosterone. This redistri-
bution was clearly blocked by mineralocorticoid receptor blockade.
The increased basolateral expression of AQP2 induced by aldosterone
may play a significant role in water metabolism in conditions with
increased sodium reabsorption in the CCD.
aquaporin-2; mineralocorticoid; water; salt; trafficking; cortical col-
lecting duct
ALDOSTERONE AND VASOPRESSIN are major hormones in the reg-
ulation of extracellular fluid volume. A potential direct role of
aldosterone in water metabolism is still unclear. As previously
demonstrated, arginine vasopressin (AVP) increases the os-
motic water permeability (Pf) in isolated, perfused collecting
ducts from normal rabbits and rats (3, 23). The increased Pf by
AVP is mediated by the vasopressin-regulated water channel
aquaporin-2 (AQP2) expressed in connecting tubule (CNT)
cells and collecting duct principal cells (10, 27, 28). Pretreat-
ment of rabbits with mineralocorticoid (in vivo, deoxycortico-
sterone) enhanced the AVP-induced increase in Pf by AVP in
the isolated, perfused cortical collecting duct (CCD) (3), sug-
gesting that mineralocorticoids may play some role in the
regulation of water balance in some species.
Previous studies have demonstrated effects of aldosterone on
AQP2 regulation. In vitro studies show that aldosterone has a
synergistic effect with vasopressin on stimulation of AQP2
expression in a mouse CCD cell line after 24 h of exposure
to the hormone (13). Animal models of aldosterone-deficient
vs. aldosterone-replaced adrenalectomized rats presented no
changes in whole-kidney AQP2 expression (18), although
segmental differences cannot be excluded. In addition to reg-
ulation of protein expression, AQP2 is regulated by trafficking
from intracellular vesicles to the apical plasma membrane,
thereby increasing Pf (27). Acutely, aldosterone has been
described to stimulate a rise in intracellular calcium (12) in
CCD cells and increase cAMP in inner medullary collecting
duct cells (31), suggesting that acute exposure to aldosterone
could be involved in the regulation of AQP2 trafficking. In
adrenalectomized rats, aldosterone deficiency has no apparent
effect on the subcellular distribution of AQP2 in the inner
medullary collecting duct (18). However, recent evidence dem-
onstrates that chronic high-dose aldosterone infusion in rats
with diabetes insipidus (e.g., lithium-induced nephrogenic di-
abetes insipidus in Brattleboro rats) induces an increase in
urine output and a marked change in subcellular redistribution
of AQP2, mainly in the CNT and CCD (26), further supporting
a potential role of aldosterone in AQP2 regulation and body
water homeostasis.
In normal rats, the effect of long-term aldosterone infusion
and possible interactive effects with dDAVP on AQP2 protein
expression and subcellular localization of AQP2 in the CCD
have not previously been studied. Here, we investigate whether
long-term aldosterone treatment alone or together with dDAVP
infusion affects 1) water homeostasis, 2) the protein expression
of AQP2, and 3) the subcellular distribution of AQP2 and Ser256
phosphorylated AQP2 (p-AQP2) compared with normal untreated
control rats and rats treated with dDAVP. The main focus of this
article is on the cortical part of the collecting duct, the part of the
collecting duct most sensitive to the effects of aldosterone.
METHODS
Experimental Protocols
All animal protocols were approved by the boards of the Institute
of Anatomy and Institute of Clinical Medicine, University of Aarhus,
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according to the licenses for use of experimental animals issued by the
Danish Ministry of Justice. Experiments were performed using male
Wistar-Hannover rats (Taconic Europe, Eiby, Denmark) or Sprague-
Dawley rats (Møllegaard Breeding Center, Skensved, Denmark) in
protocol 2. For all protocols, rats were kept individually in metabolic
cages and were allowed to acclimate for at least 3 days before
initiation of the experiments, including implantation of osmotic
minipumps. The rats were fed once daily in the morning and ate all of
the offered food during the course of the day. During the entire
experiment, there were a 12:12-h artificial light-dark cycle and a
temperature of 21  2°C. Before subcutaneous implantation of os-
motic minipumps in the neck region and intraperitoneal injection, rats
were anesthetized with isoflurane and given subcutaneous injections
of bupremorphine (Temgesic, Schering-Plough, Brussels, Belgium)
for pain relief. Osmotic minipumps (models 2001 and 2002, Alzet,
Palo Alto, CA) were prepared and equilibrated in saline for at least 4 h
at 37°C before implantation.
Protocol 1: long-term infusion of aldosterone and/or dDAVP in
rats receiving a fixed amount of food with free access to water. Male
Wistar-Hannover rats (220–240 g) were implanted with osmotic
minipumps (model 2001, Alzet) containing 1) saline mixed with
DMSO [30% vol/vol, control, n  3 (set 1)  6 (set 2)]; 2) dDAVP
(0.5 ng/h) in saline and DMSO (30% vol/vol, dDAVP, n  4  6);
3) aldosterone (150 g/day) in saline and DMSO (30% vol/vol, Aldo,
n  4  6); or 4) dDAVP (0.5 ng/h) and aldosterone (150 g/day) in
saline and DMSO (30% vol, AldodDAVP, n 4 6), respectively.
The rats were kept in metabolic cages during the following 6 days
until death. They had free access to water but a fixed daily food intake
of 17 g  rat1 day1 (normal rat chow, Altromin 1320, Petersen,
Ringsted, Denmark). For practical reasons, we established two sets of
experimental animals in this protocol. The two sets were run in
exactly the same way, and the data were compiled. In the second set,
one control rat had to be excluded due to a markedly lower food intake
for more than 2 consecutive days.
Protocol 2: long-term infusion of lower dose aldosterone in rats
receiving fixed amounts of food and water intake and spironolac-
tone treatment. An experimental set of rats which received lower dose
aldosterone with fixed food and water intake was examined to deter-
mine whether the dose of aldosterone and the increased water intake
could explain the observations made in protocol 1. This set of rats was
also used in our previous study (25). Ten male Sprague-Dawley rats
(n  14, body weight 190–210 g) were implanted with osmotic
minipumps (model 2002) delivering 50 g kg1 day1 aldosterone
(A6628, Sigma) dissolved in DMSO (25% vol/vol) and sterile saline
(75% vol/vol). Four control rats received pumps with vehicle only.
The rats received daily food rations of a food mix consisting of 15 g
rat chow (no. 1320, Altromin) and 30 ml tap water, and they ate all the
food given. The rats were then placed back into metabolic cages and
kept during the following 7 days until death. Five rats also treated with
spironolactone in addition to aldosterone infusion had 120 mg kg
body wt1 day1 spironolactone (3378, Sigma) added to the food.
After 7 days in metabolic cages, the rats were killed.
Protocol 3: long-term infusion of aldosterone in rats with clamped
plasma angiotensin II level. As aldosterone infusion could possibly
lead to a downregulation of angiotensin II levels in vivo, we per-
formed aldosterone infusion in rats with clamped angiotensin II levels.
Twelve male Wistar-Hannover rats (220–250 g) were implanted with
osmotic minipumps (model 2002, Alzet) containing angiotensin II (50
ng kg1 min1) diluted in Ringer lactate, a subpressor dose in
unrestrained rats after 1 wk (29). Two days after the implantation of
the first minipump, each rat had a second minipump (model 2001)
implanted that delivered either vehicle (n 6, saline and DMSO, 30%
vol/vol) or aldosterone (150 g/day) in saline and DMSO (30%
vol/vol, n  6), as described in protocol 1, with free water intake and
a fixed food intake of 17 g  rat1 day1. The rats were then monitored
for the following 6 days and were killed. One rat in the control group
was excluded due to an insufficient food intake.
Protocol 4: low-potassium diet-induced hypokalemia in rats with
low levels of plasma aldosterone. Given the presence of hypokalemia
in the aldosterone-treated rats and the potential effect of this factor on
AQP2 regulation, we investigated the distribution of AQP2 in the
CCD of hypokalemic rats induced by potassium restriction, who have
a low plasma aldosterone level (8). Kidney sections from 4-day
hypokalemic rats were used. Regulation of other transporters was
previously described in these rats (8). Rats were randomized into two
groups matched for body weight: a hypokalemic group (n  12) and
a control group (n  12). To produce hypokalemia, rats were fed a
potassium-deficient diet (C1037, potassium content: 0.18 g/kg chow,
Altromin) for 4 days. In the control group, rats were fed control chow
(C1000, potassium content: 7 g/kg chow, Altromin) and offered the
amount of food corresponding to the mean intake of food in the
hypokalemic group of rats during the previous day. Thus the food
intake was matched between the two groups. Rats in both groups had
free access to water throughout the experiment (8).
Protocol 5: acute aldosterone administration in rats. To under-
stand whether aldosterone has an acute effect on AQP2 redistribution
in the CCD, we studied rats acutely treated with a single dose of
Fig. 1. Time course of urine osmolality and output in protocol 1 [control (n 
8); dDAVP (n  10); aldosterone (Aldo; n  10); Aldo-dDAVP (n  10)].
Data from the 2 sets of rats in protocol 1 were pooled. Values are means SE.
A: time course of urine output from day 0 to day 6 in 4 treatment groups.
dDAVP rats presented rapidly a decrease in the urine output compared with
controls. Aldo rats presented a progressive rise in their urine output. Aldo-
dDAVP rats presented an initial decrease in their urine output before slowly
coming back to control levels. B: time course of urine osmolality from day 0
to day 6 in 4 treatment groups. dDAVP rats present an increase in their urine
osmolality, Aldo rats present a decrease in their osmolality, and Aldo-dDAVP
first present an increase in their osmolality before a return to the control level.
P  0.05 is considered significant: *different from controls; ‡different from
Aldo-dDAVP; #different from dDAVP.
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aldosterone. Twelve male Wistar-Hannover rats (230–250 g) were
given an intraperitoneal injection of either 150 g aldosterone/kg
body wt (solubilized in ethanol, then diluted in sterile saline, n  6)
or sterile saline with ethanol (n  6). This dose of aldosterone has
previously been demonstrated to induce subcellular changes in local-
ization of H-ATPase after 30 min in mice (37). After the injection,
the rats were returned to their normal cages. Thirty minutes after
injection, 6 control rats and 6 aldosterone-treated rats were killed.
Protocol 6: effect of sodium intake on AQP2 redistribution
by aldosterone. To understand the relative role of sodium reabsorption
and aldosterone in AQP2 redistribution, we studied AQP2 redistribu-
tion in the CCD of sections of rats given a chronic aldosterone
infusion along with either a sodium-deficient or sodium-replete diet.
These rats have been previously described elsewhere (18). Six male
Munich-Wistar rats were implanted with osmotic minipumps (model
2002, Alzet) delivering 200 g aldosterone (A6628, Sigma) a day.
The minipump infusion was maintained throughout the entire time
course (7 days) in all rats. The sodium intake was initially maintained
at a low level (0.32 meq Na/day) using synthetic low-sodium pow-
dered food (Altromin no.1321, Petersen) in a mixture of low-sodium
food (15 g/220 g body wt) and water (30 ml/220 g body wt). On day
4, one-half of the rats (n 3) were switched to a higher sodium intake
(2.0 mmol Na 200 g body wt1 day1) with the same amount of food
(15 g/220 g body wt) and water (30 ml/ 220 g body wt), whereas the
remaining rats (n  3) were continued on the 0.32 mmol 200 g body
wt1 day1 sodium intake.
Inhalation Anesthesia and Sampling of Blood and Tissue
Normal room air mixed with isoflurane was inhaled for anesthesia.
When the rats were sedated, a large laparotomy was performed and
the abdominal aorta was cannulated. Blood was collected from the
inferior vena cava, and subsequently the right renal artery and vein
were clamped and the right kidney was removed. Kidneys were
dissected into three different zones [cortex and outer stripe of outer
medulla (cortex/OSOM), inner stripe of outer medulla (ISOM) and
inner medulla (IM)] and were processed for immunoblotting as
described below. The left kidneys were fixed by retrograde perfusion
as described below.
Plasma Samples
The heparinized blood was centrifuged for 15 min at 4,000 g to
remove the blood cells, and subsequently the plasma was analyzed
for sodium, potassium, urea, and creatinine using a Vitros 950
(Johnson&Johnson). Osmolality was measured with an automatic
cryoscopic osmometer (Osmomat 030-D, Gonotec, Berlin, Germany).
Plasma aldosterone concentrations were determined using a commer-
cially available radioimmunoassay kit (Coat-A-Count, Diagnostic
Products, Los Angeles, CA).
Primary Antibodies
Affinity-purified polyclonal rabbit anti-rat AQP2 (H7661) was
developed against the same sequence which we have used for
LL127AP (27, 28) and has recently been characterized (26). A
commercially available mouse monoclonal antibody against rat cal-
bindin D-28K (Research Diagnostics, Flanders, NJ) was purchased,
and an antibody previously characterized against p-AQP2 (phosphor-
ylated in the PKA phosphorylation consensus site Ser-256) (5) was
used.
Semiquantitative Immunoblotting
The dissected renal cortex/OSOM, ISOM, and IM were homoge-
nized and prepared as previously described in detail (6, 26).
Kidney Fixation and Immunohistochemistry
Kidneys were fixed by perfusion via the aorta with 3% paraformalde-
hyde, in 0.1 M cacodylate buffer pH 7.4. Immunolabeling was performed
on sections from a paraffin-embedded preparation (2-m thickness) using
methods described previously in detail (6, 26).
Immunoelectron Microscopy
For immunoelectron microscopy, small pieces of kidney cortex
were cut from slices of fixed kidney, cryoprotected in 2.3 M sucrose,
and frozen in liquid nitrogen and prepared and stained for AQP2 as
described previously (4).
Semiquantitative Analysis of AQP2 Immunofluorescent Labeling
Intensity in CCD
We used two different methods for analyzing the AQP2 immuno-
fluorescent labeling intensity in CCD.
Method a. We studied five aldosterone-treated rats and five control
rats. Five CCDs in each rat were acquired randomly. All the immu-
nofluorescent images in both groups were taken on the same day with
Table 1. Serum and urinary values from protocol 1
Control (n  8) dDAVP (n  10) dDAVP-Aldo (n  10) Aldo (n  10)
PNa, mmol/l 1350.5 1300.7* 1340.8† 1350.2†‡
PK, mmol/l 4.60.2 4.80.2 30.2*† 3.10.1*‡
Purea, mmol/l 4.80.3 6.20.2 5.10.6 50.4
Posm, mosmol/kgH2O 2981.2 2891.4* 2941.9 2981.5‡
ClCr, ml/min 3.60.7 3.40.9 2.80.7 3.10.8
Paldosterone, pg/ml 27027 29621 2,09884*† 2,13076*†
FeNa, % 0.290.06 0.30.05 0.350.05 0.430.08
FeK, % 0.740.12 0.850.14 0.940.12 0.960.14
UNaV, mmol 1.540.10 1.310.06 1.430.06 1.760.08†
UKV, mmol 4.150.14 3.670.17 3.790.12 4.150.21
UNa, mmol/l 12510 24014* 1236† 783*†‡
UK, mmol/l 33516 67035* 32819† 18711*†‡
U/Posm 5.10.3 9.10.9* 5.190.4† 3.130.39*†‡
Water intake, ml 31.31 25.240.4 32.11.9† 43.42.2*†‡
Uosm, mosmol/kgH2O 1,51696 2,995162* 1,543100† 934105*†‡
Water balance, ml 16.74.2 19.50.6 20.42.6 22.42.7
Urine output, l/min 8.70.5 4.00.3* 8.40.8† 15.91.2*†‡
Values are means  SE from plasma collected at the time of death and urine collected in the final 24 h. n, No. of rats; Aldo, aldosterone; PNa, PK, Purea, Posm,
Paldosterone: plasma sodium, potassium, urea, osmolality, and aldosterone, respectively. ClCr, creatinine clearance. FENa and FEK, fractional excretion of sodium
and potassium, respectively. UNaV, UKV, UNa, UK, and Uosm: urinary sodium excretion, potassium excretion, sodium, potassium, and osmolality, respectively.
*P  0.05 compared with controls. †P  0.05 compared with dDAVP. ‡P  0.05 compared with dDAVP-Aldo.
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identical microscope settings (laser light intensity, same offset and
gain on the photomultiplier, sampling period, and averaging and
optimal focus) in blinded ways; thus the observer was not aware of the
treatment of the individual rats. Double-labeled sections for AQP2
and calbindin D-28K were used to ensure that CCDs were chosen, not
CNTs. As demonstrated in Fig. 6, every other labeled cell was marked
cross sectionally using Leica LSM software and the profile of the
immunofluorescence intensity on each cross section (from the region
of apical plasma membrane to the region of the basolateral plasma
membrane) was obtained.
Method b. The same images as used in method a were analyzed.
Using Image-Pro Plus 5 software (version 4.5.1, Media Cybernetics,
Silver Spring, MD), we performed semiquantitative analysis of AQP2
labeling intensity in the CCD of aldosterone-treated rats vs. control
rats, as previously described (26). The sum of pixel intensity in each
tubule was measured. Each cell from each tubule was then divided
into two parts at the level of the middle of the nucleus by manual
tracing (i.e., apical and basolateral cell compartments). Then, the sum
of pixel intensity on each half of the tubule was measured and the ratio
of the sum of pixel intensity in the apical or basolateral compartments
in each tubule vs. the sum of pixel intensity of the whole area of each
tubule was obtained. Cells that were partly sectioned were not in-
cluded in the analysis.
Statistical Analyses
Values are presented as means  SE. Comparisons between four
groups were made by ANOVA followed by Tukey’s multiple com-
parisons test. Multiple comparisons tests were only applied when a
significant difference (P  0.05) was determined in the ANOVA.
Two-group comparisons were made by an unpaired t-test. P values
0.05 were considered significant.
RESULTS
Long-Term Aldosterone Infusion is Associated With
Increased Urine Output and Hypokalemia, While
dDAVP Infusion Decreases Urine Output and Induces
Hyponatremia (Protocol 1)
Long-term aldosterone infusion in rats with free access to
water (protocol 1) was associated with a progressively in-
creased urine output and decreased urinary osmolality after 2
days of treatment (Fig. 1, Table 1). Water intake was also
significantly elevated in aldosterone-treated rats at day 1 and
from day 3 until the end of the experiment (data not shown).
Long-term aldosterone infusion alone or together with dDAVP
Fig. 2. Semiquantitative immunoblottting of homogenized rat
kidney tissue from the cortex and outer stripe of the outer
medulla (CTX/OSOM), inner stripe of outer medulla (ISOM),
and inner medulla (IM) obtained from control, dDAVP, Aldo,
and Aldo-dDAVP rats in protocol 1. A: representative immu-
noblot of samples from protocol 1 from 5 control and 6
dDAVP, 6 Aldo-dDAVP, and 6 Aldo rats incubated with
anti-aquaporin-2 (AQP2) antibody showing a distinct band at
27 kDa and a more diffuse band at 33–40 kDa. B: densito-
metric analysis of all animals in protocol 1 showed that the
abundance of AQP2 was increased in dDAVP rats (filled bars)
in all zones compared with controls (open bars). In Aldo-
dDAVP rats (dark grey bars), AQP2 abundance was slightly
increased in ISOM and IM compared with controls but was
significantly lower than in dDAVP rats. In Aldo rats (light gray
bars), AQP2 abundance was lower than control in ISOM
segment only. P  0.05 is considered significant: *different
from controls; ‡different from aldo-dDAVP; #different from
dDAVP.
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induced hypokalemia compared with controls (Table 1). In
contrast, dDAVP infusion decreased urine output and in-
creased urinary osmolality during the whole experimental pe-
riod (Fig. 1). In rats cotreated with aldosterone and dDAVP,
urine output decreased during the first day but then slowly went
back to control levels. The rats infused with dDAVP alone
developed hyponatremia, which was not observed when they
were cotreated with aldosterone (Table 1). The urinary
excretion rates of sodium and potassium as well as their
fractional excretion were unchanged by aldosterone alone or
aldosteronedDAVP compared with controls (Table 1). The
measurements were performed at the last day of the experi-
ments, corresponding to a steady-state period.
Decreased Protein Expression of AQP2 in ISOM of
Aldosterone-Treated Rats (Protocol 1)
Semiquantitative immunoblotting revealed that the protein
expression of AQP2 in the ISOM of aldosterone-treated rats
was significantly decreased compared with controls (Fig. 2). In
contrast, in the cortex and inner medulla, no significant
changes in AQP2 expression were noted in aldosterone-treated
rats compared with controls. In dDAVP-treated rats, AQP2
expression in the three kidney zones (cortex/OSOM, ISOM,
and IM) was significantly increased compared with controls
(Fig. 2). In rats cotreated with aldosterone and dDAVP, AQP2
expression was significantly increased in the ISOM and IM
compared with controls, but not to the same degree as in the
rats treated with dDAVP alone (Fig. 2).
Long-Term Aldosterone Infusion is Associated With
Increased AQP2 Labeling Intensity in Basolateral Domains
of CCD, While Apical AQP2 Labeling Decreases (Protocols
1 and 2)
In the CCD principal cells of normal rat kidneys, AQP2 is
known to be localized at the apical plasma membrane as
well as in the subapical intracellular vesicles (10, 28).
Consistently, immunohistochemistry revealed that most
AQP2 was localized at the apical domains of the CCD
principal cells in controls (Fig. 3A). In dDAVP-treated rats,
the overall labeling intensity of AQP2 was increased par-
ticularly at the apical plasma membrane, but also in the
basolateral plasma membrane domain (Fig. 3C). The apical
labeling intensity of AQP2 in the CCD principal cells of the
aldosterone-treated rats was decreased compared with control
rats, but there was a distinctly increased AQP2 labeling at the
basolateral plasma membrane domains (Fig. 3B). Cotreatment
with aldosterone and dDAVP was also associated with de-
creased apical AQP2 labeling and increased AQP2 labeling
intensity at the basolateral plasma membrane domains com-
pared with dDAVP alone (Fig. 3, B and D). Moreover, in
aldosterone-treated rats, immunoperoxidase labeling of p-
AQP2 also revealed strong basolateral labeling and an
apparent decrease in apical labeling of CCD principal cells
compared with controls (Fig. 4).
Since the CNT is known to exhibit basolateral AQP2 even in
the basal state (4), double immunofluorescence labeling using
antibodies against calbindin D-28K and AQP2 was undertaken
(Fig. 5) to confirm that the observed tubules were CCDs and
not CNTs. In the cortex, tubules that were negatively or only
weakly labeled with calbindin D-28K (inset in Fig. 5, A–D),
but strongly positive for AQP2, were considered CCDs,
whereas tubules positive for both AQP2 and calbindin D-28K
were considered CNTs (2) (Fig. 6, A–D). The double immu-
nofluorescent labeling confirmed that CCDs of rats treated with
aldosterone alone showed prominent basolateral staining of
AQP2 and decreased apical staining (Fig. 5B), whereas chronic
dDAVP infusion was associated mainly with strong apical
AQP2 labeling and some increase in basolateral labeling (Fig.
5C). In contrast to the CCDs, CNTs had basolateral AQP2
labeling in addition to the apical AQP2 labeling in all groups
Fig. 3. Representative micrographs showing
immunohistochemical localization of AQP2
in cortical collecting ducts (CCDs) in sec-
tions of paraffin-embedded kidneys from
control rats (A), Aldo rats (B), dDAVP rats
(C), and Aldo-dDAVP rats (D). In control
rats, the labeling for AQP2 is mainly apical,
whereas in Aldo rats, there is a high compo-
nent of basolateral AQP2 staining together
with lighter apical staining. In dDAVP rats,
AQP2 staining is stronger and mainly apical,
with some basolateral staining apparent as
well. In Aldo-dDAVP rats, there is also a
clear appearance of staining on the basolat-
eral side of the principal cells.
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(Fig. 6A). In rats treated with aldosterone, however, basolateral
staining of AQP2 in CNTs appeared more prominent and
apical AQP2 labeling appeared slightly weaker compared with
control rats (Fig. 6B). In the CNTs of aldosterone- and
dDAVP-cotreated rats, AQP2 labeling was seen in both apical
and basolateral domains (Fig. 6).
To examine whether this effect was specific to the high
(supraphysiological) aldosterone dose and/or was related to the
high water intake in protocol 1, we also examined the kidney
sections of rats which received a lower dose of aldosterone and
fixed water intake (25) (protocol 2, Fig. 7). Consistent with
protocol 1, immunohistochemistry showed a clear increase in
AQP2 labeling in the basolateral domains of CCDs (Fig. 7B)
in aldosterone-treated rats compared with controls (Fig. 7A). In
protocols 1 and 3, the height and volume of CCD cells of
aldosterone-treated rats were increased compared with controls
or dDAVP-treated rats (Figs. 3, 5, and 7).
To test whether the effects of aldosterone on AQP2 distri-
bution were mediated by activation of the mineralocorticoid
receptor, we examined the effect of spironolactone (a miner-
alocorticoid receptor antagonist) cotreatment of aldosterone-
infused rats (protocol 2). In aldosterone-infused rats cotreated
with spironolactone, the observed aldosterone-induced in-
crease in basolateral AQP2 labeling in the CCD was largely
blocked (Fig. 7C), and the labeling pattern was more similar
to untreated controls (Fig. 7A). Moreover, the aldosterone-
induced changes in CCD cell morphology (increased volume
and height) were also largely blocked by spironolactone and
the CCD appeared similar to the untreated control rats (Fig. 7,
A vs. C).
AQP2 in Basolateral Cell Domain was Situated on the
Basolateral Membrane (Protocol 1)
To investigate whether the observed basolateral AQP2 in the
CCD of aldosterone-treated rats was associated with the basolat-
eral membrane, we investigated control and aldosterone-treated
rats from protocol 1 by immunoelectron microscopy using kidney
cortex tissue sections stained for AQP2. By electron microscopy,
we observed that most basolaterally located gold-labeled AQP2 in
the CCD was situated on the basolateral membrane in aldoste-
rone-treated rats (Fig. 8).
Semiquantitative Analysis of AQP2 Immunofluorescence
Labeling in CCDs (Protocol 1)
To quantify the apparent changes in AQP2 labeling intensity
at the apical and basolateral plasma membrane domains, we
performed semiquantitative analysis of AQP2 immunofluores-
cence labeling in the CCDs in control rats vs. aldosterone-
treated rats from protocol 1 (Fig. 9).
We used Leica software (method a) to measure the pixel
intensity on the cross sections of CCD cells in the two groups
(Fig. 9, A–E). The cross-sectional pixel intensity of CCD cells
in control rats typically showed one tall peak located close or
at the apical plasma membrane domains in control rats (Fig.
9C) with none or a very small peak on the basolateral side of
the cells. Compared with control rats, the aldosterone-infused
rats had a significantly lower peak at the apical plasma mem-
brane but a second taller and broader peak on the basolateral
side of the cell (Fig. 9D). The average height of the apical and
basolateral intensity peaks in each rat was estimated and used
to compute the mean for each group (Fig. 9E). This method
will tend to underestimate the basolateral redistribution of
AQP2 on the basolateral side of the cell because the width of
the peaks, which was broader in aldosterone-treated rats, was
not taken into account. We therefore used a second semiquan-
titative method to confirm our results.
The same images as for method a were used. Using the
software program Image-Pro 5 as described in method b, we
measured the sum of the pixel intensity on the apical half
of the cells compared with the total pixel intensity of the cells.
The ratio of the pixel intensity of the apical half of the tubule
to the total tubule pixel intensity was 81.6  0.9% for control
rats vs. 50.9  2.1% for aldosterone-treated rats (P  0.001)
(Fig. 9F), with the rest of the labeling located on the basolateral
part of the cells in each group. Therefore, long-term aldoste-
rone treatment was associated with increased AQP2 labeling
intensity in the basolateral domains of CCD with a concomitant
decrease in apical labeling.
Aldosterone-Induced Increase in Basolateral AQP2 was not
due to Decreased Angiotensin II Level (Protocol 3)
In vivo and in vitro evidence suggest a potential role of
angiotensin II in the regulation of AQP2 expression and traffick-
ing (17, 19). Since long-term aldosterone infusion could reduce
Fig. 4. Representative micrographs showing immunoperoxidase staining for
Ser256- phosphorylated AQP2 (Ser256-p-AQP2) in a straight segment of CCD
in sections of paraffin-embedded kidneys from control (A) and Aldo rats (B) in
protocol 1. In the control rat, Ser-p-AQP2 is mainly visible on the apical part
of the CCD, whereas in the Aldo rat, note the appearance of strong basolateral
staining for Ser256-p-AQP2 and decreased apical staining.
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the plasma angiotensin II levels in vivo in protocols 1 and 2, we
made a new protocol to avoid the potential role of altered levels of
angiotensin II in the aldosterone-induced increase in basolateral
AQP2 expression. In protocol 3, we clamped plasma angiotensin
II levels before the aldosterone or vehicle treatment in rats.
Immunohistochemistry showed that aldosterone infusion in the
presence of angiotensin II clamping was persistently associated
with an increased basolateral labeling intensity of AQP2 in the
principal cells of the CCDs compared with rats only treated with
angiotensin II (Fig. 10, A and D).
Aldosterone-Induced Increase in Basolateral Labeling was
not Present in Hypokalemia Without Elevated
Aldosterone (Protocol 4)
Given the presence of hypokalemia in all rats receiving chronic
infusion of aldosterone, we examined whether hypokalemia per se
could play a role in the decreased apical AQP2 labeling intensity
and increased basolateral AQP2 labeling intensity observed in the
CCD. Ten-day exposure to low potassium diet-induced hypoka-
lemia has been demonstrated to decrease renal AQP2 expression
and decreased urinary concentration (20). As aldosterone-treated
rats might have suffered hypokalemia for a shorter period, the
immunohistochemistry of rats exposed to 4 days of a low-potas-
sium diet was studied (8). Rats treated with a potassium-deficient
diet for 4 days had weaker apical AQP2 labeling compared with
control rats in CCDs (Fig. 10, B and E). However, most of the
AQP2 labeling in rats on the potassium-deficient diet was seen at
the apical domains, and no labeling was observed in the basolat-
eral domains in the principal cells of CCD. This indicates that
hypokalemia induced by chronic aldosterone infusion is not likely
to play a major role in the increased basolateral AQP2 expression
observed in aldosterone-treated rats, whereas it could play a role
in the decreased expression of the apical plasma domain.
Absence of Apparent Changes in Subcellular Localization of
AQP2 in Response to Short-Term Aldosterone
Infusion (Protocol 5)
In addition to the protocols with long-term aldosterone
infusion, we examined the effect of short-term aldosterone
treatment on the subcellular redistribution of AQP2. Immuno-
histochemistry showed no increase in the basolateral AQP2
labeling 30 min after a single injection of aldosterone com-
pared with vehicle-injected rats (Fig. 10, C and F).
Sodium is Important for Redistribution of AQP2 to
the Basolateral Membrane and for Structural Changes
in the CCD in the Presence of Elevated Aldosterone
Levels (Protocol 6)
A reorganization of CCD cell morphology is a well-
described effect of chronic aldosterone treatment in rats with
normal food intake (33). However, the morphological changes
Fig. 5. Representative micrographs showing
double immunofluorescence labeling for
AQP2 and calbindin in CCD in section of
paraffin-embedded kidneys. CCDs presented
no staining for calbindin (A–D, top right
insets). AQP2 was mainly apical in control
rats (A). dDAVP (C) rats had a higher stain-
ing intensity and presented apical staining,
although basolateral AQP2 was also in-
creased. In Aldo (B) and Aldo-dDAVP rat
sections (D), the basolateral component of
AQP2 staining was even more visible and
was more important relative to apical
labeling.
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seem dependent not only on the presence of aldosterone but
also on the presence of sodium (36). Indeed the aldosterone-
induced morphological changes (increase in cell volume and in
basolateral membrane area) described in CCD principal cells
are prevented by sodium restriction (33, 36). Here, we inves-
tigated whether the basolateral expression of AQP2 in chronic
aldosterone-treated rats was also dependent on sodium intake
(protocol 6). In aldosterone-treated rats, the basolateral redis-
tribution of AQP2 was clearly reduced during sodium restric-
tion (Fig. 11) compared with normal sodium intake. Thus the
basolateral redistribution of AQP2 also appears dependent on
sodium.
DISCUSSION
The current study demonstrates that long-term aldosterone
infusion in rats with free access to water is associated with
hypokalemia, increased water intake, increased urinary excre-
tion, and decreased urinary concentration. Moreover, in CCD
principal cells, long-term aldosterone infusion induces an in-
crease in AQP2 labeling intensity in the basolateral domain and
a decrease in the apical domain of CCD principal cells relative
to controls. The increased basolateral AQP2 in CCDs in
response to long-term aldosterone infusion was still present
when angiotensin II levels were clamped and was not seen in
the presence of hypokalemia without elevated aldosterone.
Moreover, the aldosterone-induced redistribution of AQP2
appeared also dependent on sodium. Basolateral AQP2 expres-
sion was not seen acutely or in the presence of mineralocorti-
coid receptor blockade, suggesting a mineralocorticoid recep-
tor-mediated genomic mechanism.
Long-Term Aldosterone Infusion was Associated With
Increased Urine Output
Long-term aldosterone-infused rats presented with a de-
creased urine concentration and increased urine output when
the animals had free access to water, hence increased water
intake, but not when they were placed on a fixed-water diet
(25). Similar effects of aldosterone infusion on urine produc-
tion have been described in aldosterone-infused rats with both
central and lithium-induced diabetes insipidus (26) and can
here be generalized to normal rats with free water intake. The
increased urine output in aldosterone-treated rats can involve
either a central defect with an increase in thirst drive (polydip-
sia), and/or a renal effect with a decreased reabsorptive capac-
ity of the kidney, resulting in increased water loss and second-
ary increase in water intake. A central contribution is very
likely in this situation, given the absence of change of plasma
osmolality. Aldosterone is not known directly to increase
thirst; however, aldosterone-treated animals present with hy-
pokalemia, which is very well known to induce a central defect
leading to increased water intake (1), which we also observed
here. A renal defect, either primary or secondary, cannot be
Fig. 6. Representative micrographs showing
double immunofluorescence staining for
AQP2 and calbindin in connecting tubule
(CNT) in sections of paraffin-embedded kid-
neys of control (A), Aldo (B), dDAVP
(C),and Aldo-dDAVP (D) rats in protocol 1.
Calbindin was used as a marker for CNT
(A–D, top right insets). In all animals, baso-
lateral AQP2 was clearly observed in CNT.
The apical fraction of AQP2 appeared higher
in control and dDAVP rats than in Aldo and
Aldo-dDAVP rats.
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excluded in this situation. Indeed, AQP2 expression was also
decreased in the ISOM and the apical staining of AQP2 was
decreased in aldosterone-infused rats in CCDs compared with
control rats, possibly contributing to the decrease in urine
concentration observed. Therefore, a mixed effect of decreased
renal concentration ability and mostly an increased water
intake is probably the source of the observed increased urine
output in aldosterone-treated rats, with a maintained plasma
osmolality.
In rats cotreated with dDAVP and aldosterone, urinary
concentrating ability was also decreased compared with
dDAVP rats. Here also the participation of the observed
increased water intake in rats cotreated with dDAVP and
aldosterone compared with dDAVP rats cannot be excluded,
although one would expect an increased water intake to further
lower plasma osmolality in this situation, which was not the
case. Therefore, the observed decrease in AQP2 expression
in rats cotreated with dDAVP and aldosterone relative to
dDAVP rats might be important in the higher urine output of
aldosterone- and dDAVP-cotreated rats compared with
dDAVP rats.
Aldosterone Decreases AQP2 Immunolabeling Density in
Apical Membrane Domains of the CCD
In this study, a decrease in the apical expression of AQP2 in
the CCD and to a lesser extent in the CNT was observed in rats
undergoing long-term aldosterone infusion. This is a surprising
observation, since aldosterone acutely induces an increase in
cAMP in inner medullary collecting duct cells (32), which
could possibly be involved in an increase in the apical targeting
of AQP2. Moreover, a more than 24-h exposure of a mouse
CCD cell line to aldosterone and dDAVP resulted in an
increased total expression of AQP2 (13). Therefore, the ob-
served downregulation of apical AQP2 might be linked to a
more chronic and possibly indirect effect of aldosterone infu-
sion in vivo. First, the mineralocorticoid-induced hypokalemia
is likely to contribute to the decreased apical expression of
AQP2, as demonstrated in rats exposed to 4 days and previ-
ously to 10 days of a hypokalemic diet (20). Long-term
aldosterone infusion could also directly, via an unknown mech-
anism or the synthesis of other local or systemic factors, be
involved in this long-term downregulation of apical AQP2. For
example, an increase in urine output of reduced osmolality has
also been described following long-term angiotensin II in-
fusion in rats. The increased urine output was associated
with increased PGI2 production (7), possibly mediating the
decreased CCD water permeability (15). Finally, the down-
regulation of apical AQP2 may serve to limit the water
reabsorption in the CCD secondary to increased sodium
reabsorption. These potential long-term regulatory mecha-
nisms deserve further study as they might be important
in vivo for blood pressure regulation. The same hypotheses are
true for the relative downregulation of AQP2 in cortex/OSOM
and ISOM in aldosterone- and dDAVP-cotreated rats com-
pared with dDAVP rats.
Long-Term Aldosterone Infusion Induces an Increase
in Basolateral AQP2 Expression
In both control rats and dDAVP-treated rats, a high-dose
infusion of aldosterone clearly increased basolateral AQP2 and
expression in the CCD. Immunoelectron microscopy demon-
strated that most of the basolaterally located AQP2 was located
in the basal membrane itself. In addition, increased expression
AQP2 phosphorylated at Ser256, which is normally associated
with increased expression in the apical plasma membrane (21,
24), was also observed in the basolateral cell domain of CCD
Fig. 7. Representative micrographs of rat CCDs labeled for AQP2 in control
rats (A), Aldo rats (B), and Aldospironolactone (Aldo-spiro; C) rats in
protocol 4. In the paired water intake group treated with aldosterone, there is
also the appearance of clear basolateral staining for AQP2 in CCDs and lesser
apical staining. The addition of spironolactone to the food of the treated rats
reversed the effect on AQP2 subcellular distribution (C).
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cells following long-term aldosterone treatment. This suggests
that the Ser256 phosphorylation of AQP2 also may play a role
in the basolateral trafficking of AQP2.
The mechanism involved in basolateral trafficking ap-
pears not to involve a direct role of hypokalemia or changes
in plasma angiotensin II levels based on the data in the
present study. Global changes in osmolality, which in the
medulla have been associated with basolateral trafficking of
AQP2 (34), are not known to occur in the cortex. Previ-
ously, vasopressin has also been shown to induce basolateral
AQP2 expression. However, a previous study also demon-
strated increased basolateral AQP2 expression in aldoste-
rone-infused vasopressin-deficient Brattleboro rats (26). In
the present study, basolateral AQP2 expression was ob-
served in both normal rats treated with aldosterone only and
in rats cotreated with aldosterone and dDAVP and could be
blocked by spironolactone. These results further support
that aldosterone mediates the increased basolateral expres-
sion of AQP2 in CCD. Finally, in the absence of sodium, the
basolateral redistribution was in large part inhibited, indi-
cating a likely sodium dependence of this phenomenon.
The presence of basolateral localization of AQP2 is well
described in the CNTs of normal rats (4), a segment with
high sodium reabsorptive capacities (22, 30). We here
demonstrate that the increase in basolateral water channels
extends into the CCDs with long-term aldosterone treatment
in normal rats, in parallel with the known increase in the
length of the basolateral membrane and modification of cell
volume (35, 36), increase in sodium reabsorption (11, 14),
and increased expression of the basolateral Na-K-ATPase
(reviewed in Ref. 9) and AQP3 (18). All these phenomena,
including the relocation of AQP2, are potentially linked to
the increased sodium reabsorption occurring in the CCD
under high aldosterone levels. Indeed, the increased sodium
reabsorption under aldosterone treatment is expected to lead
to increased water reabsorption, hence the absence of hy-
pernatremia with aldosterone treatment. Therefore, we hy-
pothesize that in the case of the aldosterone-mediated in-
crease in sodium reabsorption in the CCD, water will be
reabsorbed through the apical membrane due to the solute
drive, potentially participating in the observed cell swelling in
the CCD. A higher permeability of the basolateral membrane,
where the osmotic gradient is low, is then possibly needed to
allow for sufficient water efflux and prevention of cell swell-
ing. The observed redistribution of AQP2 and the increased
expression of AQP3 (18) will potentially contribute to increase
basolateral membrane permeability. Moreover, some very local
changes of the osmolality at the basal side of the CCDs could
occur due to the increased sodium reabsorption in this segment.
This could then induce a secondary change in AQP2 localiza-
tion as described in the medulla (34), although the global
cortical osmolality does not change. Finally, increased baso-
lateral expression of AQP2 in the CCD has also been described
in nephrotic syndrome, another condition with markedly in-
creased sodium reabsorption in the CCD (16).
The molecular mechanisms involved in this basolateral
expression of AQP2 are currently unknown. Given the
absence of acute AQP2 redistribution in response to aldo-
sterone and its blockade by spironolactone, this effect is
very likely to be genomic in origin, with possible synthesis
and targeting of new aquaporin molecules to the basolateral
Fig. 8. Representative electron microscopic images of AQP2 immunogold labeling in cortical collecting duct from control rats (A and C) and aldosterone-treated
rats in protocol 1 (B and D) at the level of the apical membrane (A and B) and basolateral membrane (C and D). In aldosterone-treated rats, fewer gold particles
were located in the apical membrane (B) compared with controls (A). In aldosterone-treated rats, the basolateral membrane had more infoldings and more gold
particles (D) compared with controls (C). m, Mitochondria. Scale bar: 500 nm (A, C, and D) and 200 nm (B).
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membrane or redistribution of previously apical AQP2 to
the basolateral membrane. This phenomenon is likely to be
part of the global reorganization of the CCD principal cell,
described under aldosterone treatment when sodium intake
is sufficient (33). Whether the increased expression of
AQP2 on the basolateral membrane is a regulated event or
the consequence of nonregulatory expression (e.g., depend-
ing only on the changes in basolateral membrane surface
area) cannot be answered here. However, in normal rats,
very little basolateral AQP2 is seen in the CCD (4). A
further understanding of the signaling mechanisms involved
in the increased basolateral AQP2 (and AQP3) in response
to long-term aldosterone and its role in water and sodium
homeostasis requires further studies.
In summary, we have demonstrated that long-term aldo-
sterone infusion in normal rats and dDAVP-treated rats
receiving water ad libitum was associated with hypokale-
mia, increased water intake, increased urine output, and
decreased urine concentration with a decreased expression
of AQP2 in ISOM and a decreased apical expression of
Fig. 9. Semiquantification of AQP2 by immunoflu-
orescence. In method a, a profile of intensities in
cross sections is obtained. In control rats (A and C),
the staining is mainly limited to the apical side with
a clear intensity peak. In Aldo rats (B and D), we
can observe the appearance of a broad second ba-
solateral peak. The intensity of the apical peak is
also decreased compared with controls (E). In
method b, the percentage of the sum of pixel inten-
sity on each side of each tubule was calculated in
each section using Image-Pro (F). By estimating the
mean height of the apical and basal peak in each
section, a general mean for all sections could be
computed for each side, in each group. *P  0.05.
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AQP2 in the CCD. Aldosterone also induced an increase in
basolateral expression of AQP2 mostly in CCDs in rats
which appeared secondary to mineralocorticoid receptor
activation. This effect on basolateral AQP2 was independent
of hypokalemia and plasma angiotensin II levels. Further
knowledge of the functional role of basolateral AQP2 in the
CCD in situations of increased sodium reabsorption will
require further study.
Fig. 10. Control experiments. Sections from Aldo-injected, clamped, angiotensin II-treated rats (A and D) are shown. Rats hypokalemic for 4 days (B and E)
and rats acutely injected with aldosterone (C and F) were studied. Representative micrographs show immunoperoxidase staining for AQP2 in a straight segment
of CCD in sections of paraffin-embedded kidneys of control (A) and Aldo (D) rats with clamped angiotensin II levels (protocol 2). In Aldo rats, basolateral AQP2
is also apparent compared with controls. Also shown are representative micrographs showing immunoperoxidase staining for AQP2 in a straight segment of CCD
in sections of paraffin-embedded kidneys of control (B) and 4-day hypokalemic rats (HypoK; E; protocol 3). In control rats, the staining for AQP2 is mainly
located apically. In HypoK rats, the staining is also located apically, with no evidence of increased basolateral labeling. The intensity of the staining also appears
lower in HypoK rats. Also shown are representative micrographs showing immunoperoxidase staining for AQP2 in a straight segment of CCD in sections of
paraffin-embedded kidneys of control and acutely aldosterone-treated rats 30 min after the injection (protocol 5). In rats that received aldosterone treatment
acutely (F), no difference in AQP2 subcellular localization was obvious 30 min after the injection compared with their control (C).
Fig. 11. Role of sodium in basolateral
AQP2 expression. AQP2 distribution in the
CCD of chronically aldosterone-treated rats
fed a sodium-replete (A) or sodium-deficient
(C) diet were studied. B and D are higher
magnifications of boxed areas in A and C. In
the absence of a sodium-replete diet, the
increase in cell volume as well as the in-
crease in basolateral expression of AQP2 are
markedly inhibited.
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